Table 3. Clinical efficacy of afatinib in HER2 mutation NSCLC patients.
Author | Number | Male/female | Efficacy | PFS | OS |
---|---|---|---|---|---|
Mazie'res et al.[23] | 3 | NP | SD:2/PR:1 | NP | NP |
De Grève et al.[24] | 3 | 0/3 | SD:2/PR:1 | 4M | 14M |
Current study | 4 | 2/2 | SD:3/PD:1 | 3.5M | 17.75M |
Abbreviations: NP:not reported; SD: stable disease;PR:partial response;PD:progression disease;M:month